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Context The effects of Polycystic Ovary Syndrome (PCOS) on cardiovascular morbidity and 29 
mortality are unclear.  30 
Objective To establish the relative risk of myocardial infarction (MI), stroke, angina, 31 
revascularization and cardiovascular mortality for women with PCOS.  32 
Design Data were extracted from the Clinical Practice Research Datalink Aurum database. 33 
Patients with PCOS were matched to controls (1:1) by age, body mass index (BMI) category 34 
and primary care practice. The primary outcome was the time to major adverse cardiovascular 35 
event (MACE); a composite endpoint incorporating MI, stroke, angina, revascularization and 36 
cardiovascular mortality. Secondary outcomes were the individual MACE endpoints.  37 
Results Of 219,034 with a diagnosis of PCOS, 174,660 (79.7%) met the eligibility criteria and 38 
were matched. Crude rates of the composite endpoint, MI, stroke, angina, revascularization 39 
and cardiovascular mortality were respectively 82.7, 22.7, 27.4, 32.8, 10.5 and 6.97 per 40 
100,000 patient-years for cases, and 64.3, 15.9, 25.7, 19.8, 7.13 and 7.75 per 100,000 patient-41 
years for controls. In adjusted cox proportional hazard models (CPHM), the hazard ratios [HR] 42 
were 1.26 (95% confidence interval=1.13-1.41), 1.38 (1.11-1.72), 1.60 (1.32-1.94) and 1.50 43 
(1.08-2.07) for the composite outcome, MI, angina and revascularization, respectively. In a 44 
time-dependent CPHM, weight gain (HR 1.01 [1.00-1.01]), prior type 2 diabetes (T2DM) (HR 45 
2.40 [1.76-3.30]) and social deprivation (HR 1.53 [1.11-2.11]) increased risk of progression to 46 
the composite endpoint.    47 
Conclusions The risk of incident MI, angina and revascularization is increased in young 48 
women with PCOS. Weight and T2DM are potentially modifiable risk factors amenable to 49 




Polycystic Ovary Syndrome (PCOS), the commonest endocrine condition affecting young 52 
women, is characterized by hyperandrogenism, menstrual disturbance and subfertility. In 53 
addition to its well-recognised reproductive sequelae, PCOS is now established as a metabolic 54 
disorder underpinned by defects in insulin secretion and action. We and others have confirmed 55 
that these lead to an increased risk of type 2 diabetes (1).  56 
In addition to insulin resistance, women with PCOS display a range of metabolic and vascular 57 
risk factors, including central obesity (2), hypertension (3) and dyslipidaemia (4), which are 58 
commonly present at a young age. Studies have shown that surrogate markers of 59 
cardiovascular risk are increased in patients with PCOS, including carotid intima media 60 
thickness (5), endothelial dysfunction (6), coronary artery calcification (7) and arterial stiffness 61 
(8). However, whether these disturbances lead to an increased risk of vascular events and 62 
mortality is still unknown. A sub-study of the Women’s Ischemia Evaluation Study 63 
demonstrated that women with PCOS had a higher prevalence of multivessel cardiovascular 64 
disease, and significantly lower cardiovascular event-free survival, than controls (9), results 65 
which were later retracted due to a failure to replicate these findings (10) but which have been 66 
included in previous meta-analyses (11, 12). Other population-based studies have been 67 
limited by comparatively small sample sizes and/or a failure to adjust for important 68 
confounders such as obesity (13-20). We (1) and others (21, 22) have previously failed to 69 
show an increased risk of cardiovascular events in women with PCOS, albeit that these 70 
studies were likely underpowered since the crude incidence of cardio- and cerebrovascular 71 
events in this young female population is low. Longer-term population-based studies with a 72 
large sample size are therefore needed to clarify these risks further.   73 
To address these uncertainties, we re-explored vascular outcomes in women with PCOS in a 74 
large primary care research database in the UK, with a view to exploiting the greater power 75 
offered by recent extension of this dataset to provide coverage of the population on a much 76 
larger scale.  77 
 78 
Methods 79 
This was a retrospective cohort study using primary care data from the Clinical Practice 80 
Research Datalink (CPRD) Aurum database, a longitudinal, anonymized research database 81 
derived from 883 primary care practices in England. CPRD Aurum contains records for over 82 
28 million patients and is representative of the English population in terms of age, sex and 83 
deprivation23.  Approximately 70% of practices participate in a linkage scheme, by which their 84 
4 
 
patient records are linked to other data sources, including the Hospital Episode Statistics 85 
(HES) dataset, which provides data on all inpatient and outpatient contacts occurring within 86 
National Health Service hospitals in the United Kingdom, and the Office for National Statistics 87 
(ONS) mortality dataset. HES and ONS data are available for patients participating in the 88 
linkage scheme outside the period of primary care registration. 89 
 90 
Diagnostic information in CPRD Aurum is recorded using a combination of SNOMED CT (UK 91 
Edition) and Read code classification, a UK primary-care practice standard. Diagnoses in HES 92 
and ONS data are recorded using the 10th revision of the International Statistical Classification 93 
of Diseases and Related Health Problems classification (ICD-10). Surgical procedures in HES 94 
are recorded using the OPCS Classification of Interventions and Procedures version 4 (OPCS-95 
4) classification.  96 
 97 
Patient selection and matching of controls 98 
The study was undertaken using data from CPRD Aurum and linked HES and ONS mortality 99 
datasets. This study included patients identified by CPRD as being of an acceptable research 100 
quality (23), who were identified by diagnosis codes from both CPRD Aurum and HES, and 101 
who were eligible for linkage to the secondary care data. Patients with a diagnosis of PCOS, 102 
recorded in the primary-care dataset using SNOMED codes and from HES by the ICD-10 code 103 
E.28.2, from 1998 to 2017 were selected. The earliest diagnosis date was selected as the 104 
index date and only women aged 18 years or above were included.  105 
Patients with PCOS were then matched at a ratio of 1:1 to a set of non-PCOS controls. 106 
Controls were matched by age, body mass index (BMI) category (<25 kg/m2, 25-30 kg/m2, 107 
>30 kg/m2) and primary care practice. For all survival analysis, cases and controls were 108 
excluded if they had any diagnosis of myocardial infarction, stroke, angina or revascularisation 109 
before the index date along with their respective matched patient. All patients were then 110 
followed up until the earliest of: end of CPRD follow-up, end of HES follow-up, death date or 111 
date of outcome.  112 
 113 
Endpoints 114 
The primary outcome was the time to major adverse cardiovascular event (MACE); a 115 
composite endpoint incorporating myocardial infarction, stroke, angina, revascularization and 116 
cardiovascular mortality. Secondary endpoints were the individual MACE endpoints: incident 117 
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myocardial infarction, stroke, angina, revascularization and cardiovascular mortality.  118 
Myocardial infarction, stroke and angina were defined by ICD-10 codes in the HES inpatient 119 
dataset combined with a primary diagnosis and a method of admission code indicative of an 120 
emergency admission (codes 21-24). Revascularization was defined by OPCS-4 code in the 121 
HES inpatient dataset. Cardiovascular mortality was defined by ICD-10 code (I20-I25) that 122 
was considered the underlying cause of death. All outcomes were identified between 1998 123 
and 2019.  124 
 125 
Data analysis 126 
The study was powered to detect a difference in the incidence of cardiovascular events 127 
between cases and controls. Based on the results of our previous study (1) we anticipated 128 
0.3% of controls progressing to the primary endpoint. A previous meta-analysis reported an 129 
odds ratio of 1.3 for coronary heart disease in PCOS cases versus controls (24). Based on an 130 
alpha of 0.05, beta of 0.80, and a 1:1 ratio of cases:controls, this would require a sample size 131 
of 38,688 exposed cases and non-exposed controls.  132 
Baseline characteristics between cases and controls were compared using univariate 133 
statistics (t-test for continuous variables and chi-squared tests for categorical variables). 134 
Crude rates of progression to each cardiovascular outcome were presented, and time to each 135 
endpoint was analysed using Cox proportional hazards models (CPHM). Additionally, for the 136 
composite endpoint a time-dependent CPHM was implemented in the PCOS cohort with 137 
weight change in kilograms in yearly increments, using a last observation carried forward 138 
approach adjusting for patient identifier as a random effect. The CPHM models included the 139 
following covariates (all were available and tested for inclusion in each model): age, BMI 140 
category, smoking status, alcohol status, type 2 diabetes (T2DM), baseline morbidity 141 
represented by the Charlson index (25), systolic and diastolic blood pressure, and relative 142 
deprivation based on quintiles of Index of Multiple Deprivation (IMD). The IMD is an area-143 
based measure of social and material deprivation based on various criteria, including income 144 
and education. Threshold statistical significance was P ≤ 0.05, and 95% confidence intervals 145 
(CIs) were given for hazard ratios (HR). Outcomes where the CPHM was violated were not 146 
included in the analysis or where possible where censored at an earlier time frame.  147 
Two sensitivity analyses were undertaken. The first included only those patients who had a 3-148 
month “wash-in” from registration date to index date to maximize the likelihood that the case 149 
represented an incident PCOS case. The second analysis censored patient follow-up as the 150 
earlier of their ONS death date, end of HES follow-up (as defined in secondary care) or date 151 
of outcome. This allowed us to follow patients beyond their primary care registration period. 152 
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Studies using CPRD are covered by ethics approval, granted by the Trent Multicentre 153 
Research Ethics Committee (Reference 05/MRE04/87). CPRD Independent Scientific 154 
Advisory Committee approval was granted for this study (ISAC 19-166). 155 
 156 
Results 157 
Patient selection and baseline characteristics 158 
Of 219,034 women identified with a diagnosis of PCOS, 181,916 (83.1%) were eligible after 159 
application of the inclusion and matching criteria (Fig. 1). Of these, 174,660 (96.0%) were 160 
matched to controls.  161 
Median follow-up was 3.83 years (IQR = 1.89 – 7.78) for patients with PCOS and 3.00 years 162 
(IQR = 1.37 – 6.36) for controls. Median age was 29 years (IQR = 24.00 – 34.00) for both 163 
cases and controls. There were statistically significant differences between PCOS patients 164 
and controls for several baseline variables. A greater proportion of patients with PCOS were 165 
classified with extreme obesity (4.65% versus 3.12%). In addition, there were significant 166 
differences in smoking and alcohol status, Charlson index and systolic and diastolic blood 167 
pressure (Table 1).   168 
 169 
Prevalence of cardiometabolic comorbidities 170 
At baseline, 5,404 (3.09%) patients with PCOS had previously been diagnosed with type 2 171 
diabetes compared with 2,129 (1.22%) controls (p<0.001). Prior diagnosis of myocardial 172 
infarction was also higher in patients with PCOS (n = 181, 0.10%) compared with controls (n 173 
= 87, 0.05%; p<0.001). There was also a significant increase in a recorded diagnosis of stroke 174 
[PCOS 624 (0.36%) vs 525 (0.30%) controls; p = 0.004] and angina [PCOS 328 (0.19%) vs 175 
168 (0.10%) controls; p<0.001] but not revascularization [PCOS 55 (0.03%) vs 43 (0.02%) 176 
controls; p = 0.2664].  177 
 178 
Incidence of vascular events 179 
Composite endpoint 180 
In the PCOS group, there were a total 804 incident events during the follow-up period 181 
compared with 522 in the control group. The respective rates per 100,000 patient-years 182 
(100kpy) were 82.7 and 64.3, a relative-risk ratio of 1.29 (95% CI = 1.15-1.44, p<0.001). In 183 
the adjusted CPHM, the HR was 1.26 (95% CI = 1.13-1.41) (Table 2, Fig. 2a). Other covariates 184 
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that were significant in the model were smoking status, age, BMI category, T2DM, IMD quintile 185 
and systolic blood pressure. In a sensitivity analysis that excluded incident events within 3 186 
months of the index date (n=75,657), the HR remained significant at 1.33 (95% CI = 1.14-187 
1.55). In a sensitivity analysis that followed patients based on their secondary care data both 188 
the RR and HR were increased, at 1.50 (95% CI = 1.37-1.63) and 1.40 (95% CI = 1.28-1.53), 189 
respectively (Table 3). 190 
Additionally, in the time-dependent CPHM, weight increase (per kilogram) was shown to 191 
significantly increase risk (HR = 1.01, 95% CI = 1.00-1.01, p<0.001) along with type 2 192 
diabetes prior to index date (HR = 2.40, 95% CI = 1.76-3.30, p<0.001) and IMD quintile 5 193 
(HR = 1.53, 95% CI =1.11-2.11, p = 0.012) (Table 4). 194 
 195 
Myocardial Infarction 196 
In the PCOS group, there were 221 cases of first incident myocardial infarction compared 197 
with 129 in controls. The respective rates per 100kpy were 22.7 and 15.9, a relative-risk ratio 198 
of 1.43 (95% CI = 1.15–1.78, p<0.001) (Table 2). In the adjusted CPHM, the HR was 1.38 199 
(95% CI = 1.11-1.72) (Table 2, Fig. 2b). Other covariates that were significant in the model 200 
were age, smoking status, prior T2DM, systolic BP and IMD quintile. In sensitivity analysis 201 
that excluded incident events within 3 months of the index date, the HR no longer remained 202 
significant at 1.23 (95% CI = 0.92-1.64). In the additional sensitivity analysis that censored 203 
patients on secondary care data, the RR and HR were significantly increased, at 1.69 (95% 204 
CI = 1.42-2.01) and 1.53 (95% CI = 1.29-1.83), respectively (Table 3).  205 
 206 
Stroke  207 
In the PCOS group, there were 267 cases of first incident stroke compared with 209 in controls. 208 
The respective rates per 100kpy were 27.4 and 25.7, a non-significant relative-risk ratio of 209 
1.07 (95% CI = 0.92-1.32, p = 0.492). The CPHM was not calculated due to violation of the 210 
proportional hazard assumption (Table 2, Fig. 2c). In sensitivity analysis that excluded incident 211 
events within 3 months of the index date, the respective rates per 100kpy for PCOS and 212 
controls were 31.8 and 27.1, a non-significant relative-risk ratio of 1.15 (95% CI = 0.90-1.47, 213 
p = 0.276). In the additional sensitivity analysis that censored patients on secondary care data, 214 
the RR and HR were significantly increased, at 1.33 (95% CI = 1.16-1.53) and 1.26 (95% CI 215 





In the PCOS group, there were 319 cases of first incident angina compared with 161 in 219 
controls. The respective rates per 100kpy were 32.8 and 19.8, a relative-risk ratio of 1.65 220 
(95% CI = 1.37-2.00, p<0.001) (Table 2). In the adjusted CPHM, the HR was 1.60 (95% CI = 221 
1.32-1.94) (Table 2, Fig. 2d). Other covariates that were significant in the model were age, 222 
smoking status, prior T2DM, BMI, systolic BP and IMD quintile. In sensitivity analysis that 223 
excluded incident events within 3 months of the index date, the HR remained significant at 224 
2.01 (95% CI = 1.53-2.64). When patients were followed based on secondary care data the 225 
RR and HR were also significant at 1.81 (95% CI = 1.56-2.09) and 1.67 (95% CI = 1.44-1.94), 226 
respectively (Table 3). 227 
 228 
Revascularization 229 
In the PCOS group, there were 102 cases of incident revascularization compared with 58 in 230 
controls. The respective rates per 100kpy were 10.5 and 7.13, a relative-risk ratio of 1.46 (95% 231 
CI = 1.06-2.02, p = 0.019) (Table 2). In the adjusted CPHM, the HR was 1.50 (95% CI = 1.08-232 
2.07) (Table 2, Fig. 2e). Other covariates that were significant in the model were age and prior 233 
T2DM. In the wash-in sensitivity analysis the HR no longer remained significant at 1.31 (95% 234 
CI = 0.82-2.10). For the secondary care follow-up analysis, the RR and HR were significantly 235 
increased at 1.30 (95% CI = 1.01-1.66) and 1.26 (95% CI = 0.98-1.62), respectively (Table 3).  236 
 237 
Cardiovascular mortality 238 
In the PCOS group, there were 68 deaths during the follow-up period compared with 63 in the 239 
controls. The respective rates per 100kpy were 6.97 and 7.75, a non-significant relative-risk 240 
ratio of 0.90 (95% CI = 0.64-1.27, p = 0.547). The CPHM was not calculated due to violation 241 
of the proportional hazard assumption (Table 2, Fig. 2f). In the wash-in and secondary care 242 
follow-up sensitivity analyses, the relative-risk ratio remained non-significant at 1.12 (95% CI 243 
= 0.86-1.46) (Table 3). 244 
 245 
Discussion 246 
In this large retrospective analysis of electronic health record data, we found a significantly 247 
increased risk of cardiovascular events in women with PCOS compared with matched 248 
controls. The risk was increased for our composite outcome and for each of myocardial 249 
infarction, angina and revascularization individually. This is the largest study to confirm an 250 
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increased incidence of major cardiovascular morbidity in patients with PCOS and emphasizes 251 
the importance of recognizing the disorder as a higher-risk vascular condition.   252 
The biological mechanisms linking PCOS with increased vascular risk are multifactorial. 253 
Insulin resistance, which is highly prevalent in lean as well as obese women with PCOS, 254 
increases adipose tissue lipolysis (26), leading to dyslipidemia, and vasoconstriction, due to 255 
reduced endothelial nitric oxide production (27). Hyperinsulinemia may also lead to 256 
sympathoexcitation, with consequent actions on increased renal water retention and blood 257 
pressure elevation (28), whilst defects in insulin secretion as well as insulin action contribute 258 
to an increased risk of type 2 diabetes (1). Accordingly, PCOS is associated with increased 259 
endothelial dysfunction (6), arterial stiffness (8) and carotid intima media thickness (5), yet it 260 
is unclear whether these surrogate measures translate into increased vascular morbidity and 261 
mortality.   262 
Our finding of an increased risk of cardiovascular events is consistent with some (11, 24, 29, 263 
30, 31), but not all (12, 32), previous meta-analyses which have examined the risk of coronary 264 
heart disease, stroke and/or cardiovascular mortality in this population. However, two of the 265 
earlier meta-analyses were compromised by the inclusion of data that were later retracted (11, 266 
12), whilst adjustment for BMI, a potentially major confounder in this patient population, 267 
abolished the increased risk of stroke reported in another (30). At baseline, patients with 268 
PCOS in our study had a significantly increased risk of a recorded diagnosis of type 2 diabetes, 269 
myocardial infarction, stroke and angina. Our findings are largely in agreement with another 270 
population-based study, in which patients with PCOS had a higher prevalence of a recorded 271 
diagnosis of stroke, diabetes, dyslipidemia and hypertension than controls, whereas the risks 272 
of a diagnosis of cardiovascular disease (CVD), myocardial infarction and transitory cerebral 273 
ischemia were not significantly different (13). This contrasts with the findings of Lo et al who 274 
compared the prevalence of diagnosed CVD (coronary heart disease, cerebrovascular 275 
disease and peripheral vascular disease) among 11,035 women with PCOS and 55,175 age-276 
matched controls in an integrated health care delivery system in northern California (33). 277 
Despite a higher frequency of diabetes, hypertension and known dyslipidemia in women with 278 
PCOS, the prevalence of a recorded diagnosis of CVD was not different between groups, 279 
albeit that clinically diagnosed CVD as expected was very rare. 280 
In contrast to cross-sectional comparisons, longitudinal studies have largely failed to confirm 281 
an increase in incident cardiovascular events in women with PCOS, likely due to studies being 282 
underpowered as a result of the low absolute risk of cardiovascular disease in this young 283 
female population. This contrasts with the higher relative- and absolute risk reported in young 284 
patients with rheumatoid arthritis (34). In our previous examination of the CPRD dataset, we 285 
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found no evidence of an increased incidence of large vessel disease in women with PCOS 286 
(1), albeit that the number of patients studied was considerably smaller (n=21,740) than the 287 
current study. As in this study, the crude incidence of cardiovascular disease was low, 288 
reflecting the young mean age of the cohort and relatively limited median follow-up due to a 289 
greater number of patients being identified in recent years. In a Danish national register-based 290 
study (35), involving 18,112 patients and 52,769 controls, the adjusted hazard ratio for incident 291 
CVD (excluding hypertension and dyslipidemia) was 1.4 (95% CI 1.3-1.5) in PCOS patients 292 
compared with matched controls. However, their definition of CVD was very broad and 293 
included venous thrombosis/pulmonary embolism or prescription of drugs for dyslipidemia or 294 
hypertension, in addition to the more recognized definitions of CVD of myocardial infarction, 295 
angina, heart failure or cerebrovascular disease. Nevertheless, the incidence was individually 296 
increased for angina/myocardial infarction and heart failure but not stroke. In this regard, their 297 
findings are similar to ours. Hart and Doherty reported an increased risk of hospitalization for 298 
ischemic heart disease and cerebrovascular disease in their study of 2,566 women with PCOS 299 
and 25,660 age-matched women without a diagnosis of PCOS in Western Australia (15). 300 
However, they were unable to control for BMI in their study, and the selection of hospitalized 301 
patients may have led to risk inflation. In a recent systematic review and meta-analysis of 302 
observational longitudinal studies comparing fatal and non-fatal CVD events in women with 303 
and without PCOS (32), the risk of coronary events was not different between groups, whereas 304 
non-fatal cerebrovascular events were higher in women with PCOS. However, in sensitivity 305 
analyses restricted to high-quality studies, neither coronary nor cerebrovascular event risk 306 
was increased. In another meta-analysis the increased risk of cardiovascular events was 307 
noted only in reproductive age rather than menopausal women with PCOS, albeit that the 308 
number of studies conducted in older populations is low (31). Our observations, comprising a 309 
significantly larger number of events than any of the component studies which informed these 310 
meta-analyses, thus add important new data on cardiovascular morbidity in patients with 311 
PCOS.   312 
In contrast to morbidity, we found no evidence of an increased risk of cardiovascular mortality 313 
in women with PCOS in our study. In keeping with previous studies (29, 31, 32), however, the 314 
number of fatal cardiovascular or cerebrovascular events in this young premenopausal 315 
population was very low. Due to the relatively short follow-up of this young population of PCOS 316 
women, we undertook a sensitivity analysis that followed patients beyond their primary care 317 
registration period. This increased overall follow-up from a median of 3.4 years to 8.3 years, 318 
with a consequent increase in vascular events and a significantly increased hazard ratio for 319 
all of our individual morbidity outcomes. An important limitation, however, is that clinical data 320 
emanating from primary care might have been lost in any women who left their practice prior 321 
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to the end of the sensitivity follow-up period. This may introduce some uncertainty in the data, 322 
since some control women may have been diagnosed with PCOS during this time, and some 323 
patients may have left England leading to unrecognized loss of follow-up in the HES and ONS 324 
datasets. Larger studies with an extended follow-up period are therefore needed to allow us 325 
to draw meaningful conclusions on cardiovascular mortality.  326 
In our previous analysis of cardiometabolic outcomes in patients with PCOS, we found that 327 
weight gain was associated with worsening glucose tolerance, such that a 1% increase in BMI 328 
led to a 2% increase in diabetes risk (1). Hypothesizing that a similar effect might be observed 329 
with respect to vascular risk, we undertook a time-dependent CPHM analyzing weight change 330 
over time on the risk of our composite outcome. This analysis identified weight increase, a 331 
diagnosis of T2DM and relative deprivation (IMD quintile 5) as significant risk factors in the 332 
model, with a 1kg weight gain increasing the risk of the composite endpoint by 1%. These 333 
observations imply that prevention of weight gain, prevention of T2DM, and targeting 334 
resources and risk factor management to the most socially and materially deprived patients 335 
might carry the greatest traction in preventing CVD in this population. It is unclear how this 336 
might be best achieved in women with PCOS, although evidence from other patient groups 337 
with pre-diabetes suggests that intensive lifestyle interventions and/or metformin therapy 338 
might be clinically and cost-effective in reducing the subsequent incidence of T2DM (36, 37). 339 
Intervention at an early age may be especially important in light of data showing increased 340 
weight gain in early adulthood in women with PCOS compared to controls (38).  341 
International PCOS guidelines recommend an assessment of cardiovascular risk factors and 342 
global CVD risk as part of long-term patient management (39). Whilst our data provide 343 
convincing evidence of an increased risk of cardiovascular events in this condition, it is worth 344 
recognizing that the absolute risk of CVD is low, hence the case for screening is not entirely 345 
clear. Screening would only be beneficial if it led to earlier identification of risk factors 346 
amenable to modification, in turn leading to improved outcomes (40). Furthermore, in a 347 
relatively low-risk population CVD screening may be costly, of low yield and potentially harmful 348 
due to overdiagnosis. A randomized trial of screening for cardiometabolic risk factors versus 349 
usual care in women with PCOS might help provide an answer but may be practically 350 
challenging to deliver in view of the long-term follow-up needed to demonstrate an effect on 351 
event rates. Until such data are forthcoming, clinicians should at least inform patients of an 352 
increased risk of cardiometabolic disease and use clinic visits to opportunistically target 353 
modifiable risk factors, such as smoking, weight and blood pressure that were significant 354 
covariates in our individual disease models.   355 
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Our study has a number of strengths and limitations. The strengths of our study include the 356 
very large sample size, the controlled design, population setting, comparatively long follow-up 357 
period and adjustment for BMI as an important confounder in disease risk. Nevertheless, our 358 
study has several limitations, including missing data and coding imperfections due to the 359 
collation of data from routine practice. BMI was not available in one-third of cases. To 360 
compensate for this, we modelled BMI as a categorical variable, with “missing” included as a 361 
category, but it should be considered that different levels of BMI within the missing category 362 
could partially explain some of the observed results. Waist and hip circumference were 363 
additionally unavailable for analysis. Such data might offer greater insight into the risks of 364 
central compared to general obesity on event rates, although regional fat distribution may not 365 
be altered in women with PCOS (41).  As with all database studies, there is also the potential 366 
for residual confounding and bias. We were also unable to study any influence of ethnicity on 367 
risk as this is poorly recorded in the CPRD database. This is an important area of further study 368 
in view of the recognized influence of ethnicity on cardiometabolic risk factors in women with 369 
PCOS as in the general population (42, 43). An analysis of any effect on vascular events in 370 
PCOS patients after the menopausal transition would also be of interest, since 371 
hyperandrogenism and metabolic disturbances persist despite amelioration of the clinical 372 
features with age (18). Finally, we were unable to study any effects of the different PCOS 373 
phenotypes on incident vascular risk. Previous studies have suggested that cardiovascular 374 
risk factors are more prevalent in PCOS subjects with irregular cycles (44), but additional 375 
studies are needed to establish whether this leads to differences among phenotypes in clinical 376 
events.  377 
In conclusion, our study demonstrates that young women with a diagnosis of PCOS have an 378 
increased incidence of major cardiovascular events, whether captured as a composite 379 
outcome or as myocardial infarction, angina and revascularization individually. High-quality 380 
longitudinal studies are now needed to understand any effect of disease phenotype and 381 
ethnicity on risk, and whether screening strategies with targeted intervention can lead to 382 
improved cardiovascular outcomes.  383 
 384 
Data Availability Statement 385 
Restrictions apply to the availability of some or all data generated or analyzed during this study 386 
to preserve patient confidentiality or because they were used under license. The 387 
corresponding author will on request detail the restrictions and any conditions under which 388 
access to some data may be provided. 389 
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CPRD data are available upon application after ISAC approval through a licenced organisation 390 
(Pharmatelligence). Source data are not publicly available. 391 
This study is based in part on data from the Clinical Practice Research Datalink obtained under 392 
licence from the UK Medicines and Healthcare products Regulatory Agency. The data is 393 
provided by patients and collected by the NHS as part of their care and support. The 394 
interpretation and conclusions contained in this study are those of the author/s alone. 395 
HES data - Copyright © (2020), re-used with the permission of The Health & Social Care 396 
Information Centre. All rights reserved. 397 
The OPCS Classification of Interventions and Procedures, codes, terms and text is Crown 398 
copyright (2016) published by Health and Social Care Information Centre, also known as NHS 399 
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Figure 1. Attrition chart for identification of the PCOS cohort. 590 










Cases Controls p-value 
 N 174,660  174,660   
Age at index 
Median 29  29  1.000 
IQR 24.00 - 34.00  24.00 - 34.00   
Total follow-up 
(years) 
Median 3.83  3.00  <0.001 
IQR 1.89 – 7.78  1.37 – 6.36   
BMI category, n (%) 
Underweight (<18.5kg/m2) 5170  2.96% 6413  3.67% <0.001 
Normal (18.5-24.9 kg/m2)  47170 27.01% 45927 26.29%  
Overweight (25-29.9 kg/m2) 27543 15.77% 28482 16.31%  
Obese (30-39.9 kg/m2) 27868 15.96% 29609 16.95%  
Extremely Obese (≥40 kg/m2) 8129 4.65% 5449 3.12%  
Missing 58780 33.65% 58780 33.65%  
Smoking Status, n (%) 
Never 103591 59.31% 102888 58.91% <0.001 
Prior 23085 13.22% 20336 11.64% 
 
Current 43915 25.14% 44060 25.23% 
 
Missing 4069 2.33% 7376 4.22% 
 
Alcohol Status, n (%) 
Never 22131 12.67% 19375 11.09% <0.001 
Prior 1001 0.57% 903 0.52% 
 
Current 43876 25.12% 40886 23.41% 
 
Missing 107652 61.64% 113496 64.98% 
 
Charlson Index 
Mean 0.37  0.30  <0.001 
SD 0.00  0.00   
Systolic BP, n (%) 
<120 mmHg 53268 30.50% 48264 27.63% <0.001 
120-139 mmHg 41909 23.99% 38485 22.03%  
>139 mmHg 7678 4.40% 5358 3.07%  
Missing 71805 41.11% 82553 47.26%  
Diastolic BP, n (%) 
<80 mmHg 68173 39.03% 64456 36.90% <0.001 
80-89 mmHg 27239 15.60% 23152 13.26%  
>89 mmHg 7443 4.26% 4499 2.58%  
Missing 71805 41.11% 82553 47.26% 
 
Index of Multiple 
Deprivation, n (%) 
Quintile 1 33732 19.31% 33643 19.26% 0.479 
Quintile 2 33338 19.09% 33102 18.95%  
Quintile 3 34894 19.98% 34688 19.86%  
Quintile 4 38657 22.13% 38933 22.29%  
Quintile 5 34039 19.49% 34294 19.63%  
Prior Comorbidities 
Type 2 diabetes 5404 3.09% 2129 1.22% <0.001 
Myocardial Infarction 181 0.10% 87 0.05% <0.001 
Stroke 624 0.36% 525 0.30% 0.004 
Angina 328 0.19% 168 0.10% <0.001 




Table 2. Number, crude rates, and associated hazard ratios for incident cardiovascular events in women with PCOS and matched controls. 
CV outcome 
Cases (N=172,907) Controls (N=172,907) 
RR (95% CI) p-value HR (95% CI) p-value 
Number Rate (100kpy) Number Rate (100kpy) 
Composite endpoint 804 82.7 522 64.3 1.29 (1.15-1.44) <0.001 1.26 (1.13-1.41) <0.001 
MI 221 22.7 129 15.9 1.43 (1.15-1.78) 0.001 1.38 (1.11-1.72) 0.004 
Stroke* 267 27.4 209 25.7 1.07 (0.92-1.32) 0.492 - - 
Angina 319 32.8 161 19.8 1.65 (1.37-2.00) <0.001 1.60 (1.32-1.94) <0.001 
Revascularization 102 10.5 58 7.13 1.46 (1.06-2.02) 0.019 1.50 (1.08-2.07) 0.015 
CV mortality* 68 6.97 63 7.75 0.90 (0.64-1.27) 0.547 - - 
*The Cox proportional hazards model was not presented as it violated the assumptions of proportional hazards
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Table 3. Number, crude rates, and associated hazard ratios for incident cardiovascular events in women with PCOS and matched controls – 
sensitivity analysis censoring patients based on secondary care data. 
*The Cox proportional hazards model was not presented as it violated the assumptions of proportional hazards. 
 
CV outcome 
Cases (N=172,907) Controls (N=172,907) 
RR (95% CI) p-value HR (95% CI) p-value 
Number Rate (100kpy) Number Rate (100kpy) 
Composite endpoint 1,305 81.0 872 54.1 1.50 (1.37-1.63) <0.001 1.40 (1.28-1.53) <0.001 
MI 345 21.4 204 12.6 1.69 (1.42-2.01) <0.001 1.53 (1.29-1.83) <0.001 
Stroke 463 28.7 347 21.5 1.33 (1.16-1.53) <0.001 1.26 (1.10-1.45) 0.001 
Angina 512 31.7 283 17.5 1.81 (1.56-2.09) <0.001 1.67 (1.44-1.94) <0.001 
Revascularization 144 8.9 111 6.9 1.30 (1.01-1.66) 0.039 1.26 (0.98-1.62) 0.039 
CV mortality* 119 7.4 106 6.6 1.12 (0.86-1.46) 0.389 - - 
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Table 4. HRs derived from the time-dependent Cox proportional hazard model for the composite endpoint in the PCOS cohort. 
 
Variables HR (95% CI) p-value 
Weight increase (kg) 1.01 (1.00-1.01) <0.001 
Prior Type 2 diabetes 2.40 (1.76-3.30) <0.001 
IMD (ref = Quintile 1)   
Quintile 2  0.97 (0.68-1.38) 0.882 
Quintile 3 1.26 (0.91-1.75) 0.091 
Quintile 4 1.14 (1.82-1.60) 0.447 
Quintile 5 1.53 (1.11-2.11) 0.012 


